account_id none on file
legal_name Adicet Bio, Inc.
ticker ACET
cik 1720580
domain adicetbio.com
linkedin_company_url https://www.linkedin.com/company/adicet-bio-inc
entry_point_account_id none on file
name Adicet Bio Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 12 executives 0 family 0
why_nownone on file
callsnone on file
filings
(3) Relates to other expenses primarily for software subscriptions and licenses, office expenses, travel and entertainment, director compensation and recruiting fees.
filing / Aug 5, 2026 / receipt
We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.
filing / Aug 5, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
filing / Aug 5, 2026 / receipt
Additionally, we operate in a hybrid work environment. As our employees and our business partners’ employees work from home and access our systems remotely, we may be subject to heightened security and privacy risks, including the risks of cyber attacks and privacy incidents.
filing / Aug 5, 2026 / receipt
In July 2025, we implemented our workforce reduction plan. In connection with the workforce reduction plan, we incurred costs of approximately $2.3 million, which were primarily one-time severance benefits.
filing / Aug 5, 2026 / receipt
In connection with the workforce reduction plan, we incurred costs of approximately $2.3 million, which were primarily one-time severance benefits.
filing / Aug 5, 2026 / receipt
(3) Relates to other expenses primarily for software subscriptions and licenses, office expenses, travel and entertainment, director compensation and recruiting fees.
filing / May 13, 2026 / receipt
We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.
filing / May 13, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.
filing / May 13, 2026 / receipt
Additionally, we operate in a hybrid work environment. As our employees and our business partners’ employees work from home and access our systems remotely, we may be subject to heightened security and privacy risks, including the risks of cyber attacks and privacy incidents.
filing / May 13, 2026 / receipt
In July 2025, we implemented our workforce reduction plan. In connection with the workforce reduction plan, we expect to incur costs of approximately $2.3 million, which are primarily one-time severance benefits.
filing / May 13, 2026 / receipt
In connection with the workforce reduction plan, we expect to incur costs of approximately $2.3 million, which are primarily one-time severance benefits.
filing / May 13, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-04 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug adicet-bio-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$